**Molbio Diagnostics Limited**
(Formerly Molbio Diagnostics Private Limited)
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

**Date: November 05, 2026**

To

BSE Limited("BSE")
Phiroze Jeejeebhoy Towers
2nd Floor, Dalal Street
Mumbai- 400001

National Stock Exchange of India Ltd("NSE")
Exchange Plaza
Bandra-Kurla Complex, Bandra (E)
Mumbai- 4000051

BSE Scrip Code: 544866

Symbol: MOLBIO

**Subject: Outcome of Board Meeting held on Thursday, November 05,2026 pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

Dear Sir/Ma'am,

Pursuant to Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("SEBI Listing Regulations") along with relevant SEBI circulars, as applicable, we wish to inform that the Board of Directors of Molbio Diagnostics Limited ("Company"), at its meeting held today i.e. Thursday, November 05, 2026 has, inter-alia, transacted the following businesses:

1. Approval of Un-audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.

2. The said Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half-year ended September 30, 2026, prepared in terms of Regulation 33 of the Listing Regulations together with Limited Review Report, are enclosed herewith as "**Annexure-A".**

   The Company hereby declares that the Statutory Auditor have expressed an unmodified opinion in the Limited Review Report on the Financials Results for the quarter and half year ended September 30, 2026 under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

3. Approval of Monitoring Agency Report on the utilization of proceeds from the Initial Public Offer (IPO) of the company for the quarter ended September 30, 2026 pursuant to regulation 32 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as approved by the Audit Committee of the Company.

4. Noting of resignation of Dr. Kuldeep Singh Sachdeva, President & Chief Medical Officer, Senior Management Personnel (SMP) of the company.

   The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as amended from time to time are enclosed here as **"Annexure-B".**

5. Appointment of M/s. Rakesh Hulihalli & Associates, Practising Company Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714), as the Secretarial Auditor of the Company for a term of five

**Molbio Diagnostics Limited**
(Formerly Molbio Diagnostics Private Limited)
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

consecutive financial years commencing from FY 2026-27 and ending with FY 2030-31, subject to the approval of the members of the Company.

The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as amended from time to time are enclosed here as **"Annexure-C".**

6. Approval of Notice of Postal Ballot through remote e-voting process and to authorise Director/KMP to decide the cut-off date and to dispatch the notice of Postal Ballot to the eligible members of the Company.

The Board Meeting commenced at 03.36 P.M and concluded at 04.03 P.M.

The above intimation is also available on the Company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to kindly take the same on record.

Thanking You.
Yours Faithfully,

**For Molbio Diagnostics Limited**

DARSHAN RAGHUNATH KAREKAR
Digitally signed by DARSHAN RAGHUNATH KAREKAR
Date: 2026.11.05 17:21:12 +05'30'

**Darshan Raghunath Karekar**
**Company Secretary & Compliance Officer**
**M.No: F13569**
**Date: November 05, 2026**
**Place: Verna-Goa**

**S.R. BATLIBOI & ASSOCIATES LLP**
Chartered Accountants

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**
**The Board of Directors**
**Molbio Diagnostics Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Molbio Diagnostics Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The comparative financial information of the Company for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 included in the accompanying unaudited standalone financial results, were not reviewed or audited by us and have been compiled by the Management and approved by the Board of Directors of the Company.

**For S.R. BATLIBOI & ASSOCIATES LLP**
Chartered Accountants
**ICAI Firm registration number:** 101049W/E300004

**per Sandeep Karnani**
Partner
Membership No.: 061207

UDIN: 26061207ZDNFBS6377
Place: Bengaluru
Date: November 05, 2026



**Molbio Diagnostics Limited**
(formerly Molbio Diagnostics Private Limited)
CIN: L33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Unaudited Standalone Statement of Assets and Liabilities as of September 30, 2026**

(Amount in ₹ Million, except as stated otherwise)

| | Particulars | As at September 30, 2026 | As at March 31, 2026 |
|---|---|---|---|
| | | Unaudited | Audited |
| I | **Assets** | | |
| (1) | **Non-current assets** | | |
| | (a) Property, plant and equipment | 2,169.87 | 2,267.22 |
| | (b) Capital work-in-progress | 158.58 | 56.18 |
| | (c) Other intangible assets | 2.24 | 3.40 |
| | (d) Right-of-use assets | 295.07 | 303.25 |
| | (e) Financial assets | | |
| | (i) Investments | 3,175.85 | 3,174.37 |
| | (ii) Loans | 140.00 | 140.00 |
| | (iii) Other financial assets | 247.02 | 294.71 |
| | (f) Deferred tax assets (net) | 483.51 | 482.79 |
| | (g) Non-current tax assets (net) | 160.02 | 62.42 |
| | (h) Other assets | 571.53 | 586.63 |
| | | **7,403.69** | **7,370.97** |
| (2) | **Current assets** | | |
| | (a) Inventories | 3,919.54 | 3,967.42 |
| | (b) Financial assets | | |
| | (i) Trade receivables | 2,787.30 | 3,585.52 |
| | (ii) Cash and cash equivalents | 2,662.52 | 1,090.66 |
| | (iii) Bank balances other than (ii) above | 753.93 | - |
| | (iv) Loans | - | 9.35 |
| | (v) Other financial assets | 517.93 | 196.52 |
| | (c) Other assets | 1,564.84 | 1,185.88 |
| | | **12,206.06** | **10,035.35** |
| | **Total assets (1+2)** | **19,609.75** | **17,406.32** |
| II | **Equity and liabilities** | | |
| (1) | **Equity** | | |
| | (a) Equity share capital | 115.24 | 112.76 |
| | (b) Other equity | 14,052.82 | 11,234.33 |
| | **Total equity** | **14,168.06** | **11,347.09** |
| (2) | **Non-current liabilities** | | |
| | (a) Financial liabilities | | |
| | (i) Borrowings | 1,827.22 | 2,111.24 |
| | (ii) Lease liabilities | 73.51 | 77.64 |
| | (b) Net employee defined benefit liabilities | 44.24 | 55.06 |
| | | **1,944.97** | **2,243.94** |
| (3) | **Current liabilities** | | |
| | (a) Financial liabilities | | |
| | (i) Borrowings | 575.32 | 1,234.62 |
| | (ii) Lease liabilities | 37.15 | 36.18 |
| | (iii) Trade payables | | - |
| | (a) Total outstanding dues of micro enterprises and small enterprises | 213.35 | 166.41 |
| | (b) Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,574.68 | 1,629.93 |
| | (iv) Other financial liabilities | 204.04 | 308.34 |
| | (b) Net employee defined benefit liabilities | 10.00 | 3.50 |
| | (c) Provisions | 197.89 | 194.27 |
| | (d) Other liabilities | 684.29 | 242.04 |
| | | **3,496.72** | **3,815.29** |
| | **Total liabilities (2+3)** | **5,441.69** | **6,059.23** |
| | **Total equity and liabilities (1+2+3)** | **19,609.75** | **17,406.32** |

S.R. Batliboi & Associates LLP Bengaluru

Place: Goa
Date: November 05, 2026

For and on behalf of the Board of Directors of
Molbio Diagnostics Limited (formerly Molbio Diagnostics Private Limited)

MOLBIO DIAGNOSTICS LIMITED GOA

**Sangeetha Sriram**
Executive Director
DIN: 02103165

**Molbio Diagnostics Limited**

(formerly Molbio Diagnostics Private Limited)

CIN: L33125GA2000PLC002909

Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722

Phone no: +91 832 6724888 . Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Statement of unaudited standalone financial results for the quarter and six months ended September 30, 2026**

**(Amount in ₹ Million, except as stated otherwise)**

| | Particulars | Quarter ended | | | Six months ended | | Year ended |
|---|---|---|---|---|---|---|---|
| | | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | March 31, 2026 |
| | | Unaudited | Unaudited | (Refer note 10) | Unaudited | (Refer note 10) | Audited |
| I | **Income** | | | | | | |
| | Revenue from operations | 2,488.79 | 3,993.78 | 5,793.11 | 6,482.57 | 6,746.31 | 13,133.98 |
| | Other income | 39.71 | 13.68 | 15.90 | 53.39 | 30.72 | 77.15 |
| | **Total income** | **2,528.50** | **4,007.46** | **5,809.01** | **6,535.96** | **6,777.03** | **13,211.13** |
| II | **Expenses** | | | | | | |
| | Cost of raw material and components consumed | 995.69 | 1,267.24 | 1,580.12 | 2,262.93 | 2,426.57 | 4,849.90 |
| | Purchase of traded goods | 31.20 | 60.92 | 31.10 | 92.12 | 37.15 | 49.30 |
| | (Increase) / decrease in inventories of finished goods, work-in-progress and traded goods | (122.17) | 114.35 | 578.35 | (7.82) | 123.08 | 156.26 |
| | Employee benefit expenses | 145.66 | 247.56 | 214.09 | 393.22 | 376.47 | 812.26 |
| | Depreciation and amortisation expenses | 139.93 | 84.18 | 87.46 | 224.11 | 161.60 | 357.33 |
| | Finance costs | 62.68 | 86.62 | 39.13 | 149.30 | 58.01 | 231.54 |
| | Other expenses | 851.98 | 1,387.35 | 2,047.09 | 2,239.33 | 2,537.09 | 4,747.68 |
| | **Total expenses** | **2,104.97** | **3,248.22** | **4,577.34** | **5,353.19** | **5,719.97** | **11,204.27** |
| III | **Profit / (loss) before tax and exceptional item (I - II)** | **423.53** | **759.24** | **1,231.67** | **1,182.77** | **1,057.06** | **2,006.86** |
| IV | Exceptional item (refer note 5) | - | - | - | - | - | 31.34 |
| V | **Profit / (loss) before tax (III - IV)** | **423.53** | **759.24** | **1,231.67** | **1,182.77** | **1,057.06** | **1,975.52** |
| VI | **Tax expenses** | | | | | | |
| | (a) Current tax | 82.14 | 221.99 | 299.02 | 304.13 | 299.02 | 599.74 |
| | (b) Deferred tax (credit) / charge | 27.61 | (29.02) | 13.05 | (1.41) | (27.51) | (70.51) |
| | **Total tax expenses** | **109.75** | **192.97** | **312.07** | **302.72** | **271.51** | **529.23** |
| VII | **Profit / (loss) for the period / year (V - VI)** | **313.78** | **566.27** | **919.60** | **880.05** | **785.55** | **1,446.29** |
| VIII | **Other comprehensive income / (loss)** | | | | | | |
| | Other comprehensive income / (loss) not to be reclassified to profit or loss: | | | | | | |
| | (i) Re-measurement gains / (losses) on defined benefit plan | 3.58 | (0.84) | (0.40) | 2.74 | **(2.71)** | 0.11 |
| | Income tax effect on above | (0.90) | 0.21 | 0.10 | (0.69) | **0.68** | (0.03) |
| | **Total other comprehensive income / (loss) for the period / year (net of tax)** | **2.68** | **(0.63)** | **(0.30)** | **2.05** | **(2.03)** | **0.08** |
| IX | ***Total comprehensive income / (loss) for the period / year (net of tax) (VII + VIII)*** | **316.46** | **565.64** | **919.30** | **882.10** | **783.52** | **1,446.37** |
| X | **Paid-up equity share capital (face value ₹ 1 each fully paid)** | **115.24** | **112.76** | **112.76** | **115.24** | **112.76** | **112.76** |
| XI | **Other equity** | | | | | | **11,234.33** |
| XII | **Earnings per equity share (EPS) (face value - ₹ 1 each) (not annualised except for year end EPS) (Refer Note 9)** | | | | | | |
| | Basic EPS (₹) | 2.75 | 5.02 | 8.16 | 7.76 | 6.97 | 12.83 |
| | Diluted EPS (₹) | 2.75 | 5.02 | 8.16 | 7.76 | 6.97 | 12.83 |

See accompanying notes to the unaudited standalone financial results

S.R. Batliboi & Associates LLP Bengaluru

MOLBIO DIAGNOSTICS LIMITED GOA

**Molbio Diagnostics Limited**
(formerly Molbio Diagnostics Private Limited)
CIN: L33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Unaudited Standalone Statement of Cash Flows for the six months ended September 30, 2026**

**(Amount in ₹ Million, except as stated otherwise)**

| Particulars | Six months ended | |
|---|---|---|
| | September 30, 2026 | September 30, 2025 |
| | Unaudited | Unaudited |
| **A. Cash flows from / (used in) operating activities** | | |
| **Profit before tax** | **1,182.77** | **1,057.06** |
| **Adjustments to reconcile profit before tax to net cash flows:** | | |
| Depreciation and amortisation expenses | 224.11 | 161.60 |
| Impairment allowance on trade receivables and advances | (15.75) | 88.22 |
| Provision for inventories obsolescence | 68.75 | 40.00 |
| Bad debts / advances written off | - | 6.58 |
| Unrealised (gain) / loss on account of foreign exchange fluctuation (net) | (13.53) | 11.91 |
| Gain on termination of lease contracts | (0.33) | - |
| Gain on sale / discard of property, plant and equipment (net) | (0.21) | - |
| Interest income | (37.75) | (19.81) |
| Finance costs | 143.75 | 52.09 |
| Share based payments to employees | 12.06 | - |
| **Operating profit before working capital changes** | **1,563.87** | **1,397.65** |
| Working capital adjustments : | | |
| (Increase) / decrease in inventories | (20.87) | (146.39) |
| Decrease / (increase) in trade receivables | 810.40 | (3,532.15) |
| (Increase) / decrease in non-current and current other financial and other assets | (104.50) | (274.10) |
| Increase / (decrease) in trade payables, non-current and current other financial, other liabilities and provisions | 354.76 | 559.59 |
| **Cash generated from operations** | **2,603.66** | **(1,995.40)** |
| Direct taxes paid (net of refund) | (401.73) | (315.89) |
| **Net cash flows from / (used in) operating activities (A)** | **2,201.93** | **(2,311.29)** |
| **B. Cash flows (used in) / from investing activities** | | |
| Purchase of property, plant and equipment (including capital work-in- progress, capital advances and payable towards capital goods) and Intangible assets | (284.53) | (174.03) |
| Proceeds from sale of property plant and equipment | 0.38 | 0.40 |
| Interest income received | 38.25 | 3.34 |
| (Investment) / redemption in bank deposits (net) | (1,214.77) | (25.81) |
| Loans given to related parties | - | (51.00) |
| Loan repaid by related parties | 9.35 | - |
| Investment in compulsorily convertible preference shares | (1.48) | - |
| **Net cash flows (used in) / from investing activities (B)** | **(1,452.80)** | **(247.10)** |
| **C. Cash flow from / (used in) financing activities** | | |
| Proceeds from issue of equity shares | 2,000.00 | - |
| Payment of share issue expenses (net) | (73.19) | - |
| Payment of principal portion of lease liabilities | (18.13) | (17.94) |
| Payment of interest portion of lease liabilities | (5.12) | (3.71) |
| Repayment of long-term borrowings | (52.04) | (55.97) |
| (Repayment) / proceeds from short-term borrowings (net) | (886.05) | 782.54 |
| Finance costs paid | (142.74) | (46.20) |
| **Net cash flows from / (used in) financing activities (C)** | **822.73** | **658.72** |
| **Net increase / (decrease) in cash and cash equivalents (A+B+C)** | 1,571.86 | (1,899.67) |
| Cash and cash equivalents at the beginning of the year | 1,090.66 | 1,107.69 |
| **Cash and cash equivalents at the end of the period** | **2,662.52** | **(791.98)** |
| **Components of cash and cash equivalents** | | |
| Balances with banks | | |
| - On current accounts | 1,304.23 | 42.79 |
| - Deposits with original maturity less than 3 months | 1,357.52 | - |
| Cash on hand | 0.77 | 0.72 |
| Overdraft from bank | - | (835.49) |
| **Total cash and cash equivalents** | **2,662.52** | **(791.98)** |

Place : Goa
Date : November 05, 2026

S.R. Batliboi & Associates LLP Bengaluru

MOLBIO DIAGNOSTICS LIMITED GOA

**For Molbio Diagnostics Limited**

**Sangeetha Sriram**
Executive Director
DIN: 02103165

**Notes**

1 The Statement of unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of Molbio Diagnostics Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on November 05, 2026. The statutory auditors have conducted a limited review of the above unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026

2 The Statement of unaudited standalone financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of the Company has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 During the quarter and six months ended September 30, 2026, the Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of ₹ 1 each at an issue price of ₹ 807 per equity share to investors and at an issue price of ₹ 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to ₹ 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to ₹ 7,396.96 Million. The Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026.

Further, out of the total proceeds of ₹ 2,000.00 Million raised through the fresh issue pursuant to IPO, the Company is in the process of utilisation of the proceeds towards the objects of the Offer as disclosed in the offer document and the unutilised proceeds are temporarily invested in fixed deposit and other bank balances

4 The shareholders of the Company through a special resolution approved the 'Employee Stock Option Plan 2025 ("ESOP 2025")/ "Plan") for creation of ESOP pool of 2,819,000 options having face value of ₹ 1/- each. During the quarter ended September 30, 2026, the Company granted 854,480 options to the employees of the Company and its subsidiaries, of which 5,656 options have been forfeited.

5 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the 'New Labour Codes'. The Company had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by ₹ 23.15 Million and increase in leave liability (compensated absences) by ₹ 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules thereto

6 A survey under Section 133A of the Income-tax Act, 1961 ("IT Act"), was carried out at the premises of the Company, by the Income Tax authorities during the year ended March, 2024, followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Company.

The department has raised tax demands aggregating to ₹ 208.71 Million plus interest and penalty, as applicable, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications.

Management believes that the Company has complied with all the applicable provisions of the IT Act with respect to its operations. The Company has paid an amount of ₹ 78.95 Million as at September 30, 2026 under protest in connection with the survey. The management of the Company is confident of favourable outcome and accordingly no adjustments have been made in the unaudited standalone financial results for the quarter and six months ended September 30, 2026 in this regard.

7 a. During the year ended March 31, 2025, the Company, OptraSCAN, Inc. ("OptraSCAN"), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of ₹ 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Company. Further, during the year ended March 31, 2026, the Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of ₹2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Company's shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Company.

b. As at March 31, 2026, the Company held a stake of 65.47% in Prognosys Medical Systems Private Limited ("PMS"). During the quarter ended June 30, 2026, the Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Company's cumulative shareholding in PMS increased from 65.47% to 70.00%.

8 The operating segment of the Company is identified to be "manufacturing of diagnostic devices, chips, reagents, etc" and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 "Operating segments" and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Company.

9 During the quarter ended September 30, 2025, the Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Companies Act, 2013 in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of ₹ 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended September 30, 2025 and six months ended September 30, 2025 have been adjusted retrospectively and presented accordingly.

10 The financial results for the quarter ended September 30, 2025 represent the balancing figures between the unaudited financial results for the six months ended September 30, 2025 and the unaudited financial results for the quarter ended June 30, 2025, both of which were compiled by management. Neither the financial results for the quarter ended September 30, 2025 and six months ended September 30, 2025 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.

Place: Goa
Date: November 05, 2026

S.R. Batliboi & Associates LLP
Bengaluru

**For Molbio Diagnostics Limited**

MOLBIO DIAGNOSTICS LIMITED
GOA

**Sangeetha Sriram**
Executive Director
DIN: 02103165

**S.R. BATLIBOI & ASSOCIATES LLP**
Chartered Accountants

12th Floor
"UB City" Canberra Block
No. 24, Vittal Mallya Road
Bengaluru - 560 001, India
Tel : +91 80 6648 9000

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**
**The Board of Directors**
**Molbio Diagnostics Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Molbio Diagnostics Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

| S. No. | Name of the Entity | Relationship |
|---|---|---|
| 1 | Molbio Diagnostics Limited | Holding Company |
| 2 | Bigtec Private Limited | Subsidiary |
| 3 | OptraScan INC | Subsidiary |
| 4 | OptraScan India Private Limited | Subsidiary |
| 5 | Prognosys Medical Systems Private Limited | Subsidiary |
| 6 | Prognosys Healthcare (India) Private Limited | Subsidiary |
| 7 | Chayagraphics (India) Private Limited | Associate |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards

S.R. Batliboi & Associates LLP Bengaluru

('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

   - Four subsidiaries, whose unaudited interim financial results include total assets of ₹ 3,770.54 Million as at September 30, 2026, total revenues of ₹ 136.67 Million and ₹ 261.87 Million, total net loss after tax of ₹ 190.19 Million and ₹ 320.46 Million , total comprehensive loss of ₹ 154.39 Million and ₹ 286.32 Million, for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 respectively, and net cash outflows of ₹ 218.06 Million for the period from April 01, 2026 to September 30, 2026 as considered in the Statement which have been reviewed by their respective independent auditors.

   - One associate, whose unaudited interim financial results include the Group's share of net loss of ₹ Nil Million and ₹ 0.01 Million and the Group's share of total comprehensive loss of ₹ Nil Million and ₹0.01 Million for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 respectively, as considered in the Statement whose interim financial results and other financial information has been reviewed by their respective independent auditors.

   The independent auditor's reports on unaudited interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement in respect of matters stated in paragraph 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

7. The comparative consolidated financial information of the Group for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 included in the accompanying unaudited consolidated financial results, were not reviewed or audited by us and have been compiled by the Management and approved by the Board of Directors of the Holding Company.

**For S.R. Batliboi & Associates LLP**
Chartered Accountants
**ICAI Firm registration number:** 101049W/E300004

**per Sandeep Karnani**
Partner
Membership No.: 061207

S.R. Batliboi & Associates LLP Bengaluru

UDIN: 26061207GECRMW2398
Place: Bengaluru
Date: November 05, 2026

**Molbio Diagnostics Limited**
(formerly Molbio Diagnostics Private Limited)
CIN: L33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Unaudited Consolidated Statement of Assets and Liabilities as of September 30, 2026**

(Amount in ₹ Million, except as stated otherwise)

| | Particulars | As at September 30, 2026 | As at March 31, 2026 |
|---|---|---|---|
| | | Unaudited | Audited |
| I | **Assets** | | |
| (1) | **Non-current assets** | | |
| | (a) Property, plant and equipment | 2,433.28 | 2,480.82 |
| | (b) Capital work-in-progress | 175.54 | 113.21 |
| | (c) Goodwill | 621.28 | 621.28 |
| | (d) Other intangible assets | 1,597.51 | 1,708.05 |
| | (e) Right-of-use assets | 549.84 | 553.56 |
| | (f) Investments accounted for using equity method | 59.76 | 59.77 |
| | (g) Financial assets | | |
| | (i) Investments | 0.03 | 0.03 |
| | (ii) Other financial assets | 555.90 | 819.25 |
| | (h) Deferred tax assets (net) | 525.93 | 515.53 |
| | (i) Non-current tax assets (net) | 299.53 | 168.80 |
| | (j) Other assets | 577.16 | 595.52 |
| | | **7,395.76** | **7,635.82** |
| (2) | **Current assets** | | |
| | (a) Inventories | 4,562.63 | 4,492.62 |
| | (b) Financial assets | | |
| | (i) Trade receivables | 3,023.29 | 4,087.36 |
| | (ii) Cash and cash equivalents | 4,931.28 | 3,555.30 |
| | (iii) Bank balances other than (ii) above | 761.26 | 115.79 |
| | (iv) Other financial assets | 833.27 | 255.27 |
| | (c) Other assets | 1,779.39 | 1,342.08 |
| | | **15,891.12** | **13,848.42** |
| | **Total assets (1+2)** | **23,286.88** | **21,484.24** |
| II | **Equity and liabilities** | | |
| (1) | **Equity** | | |
| | (a) Equity share capital | 115.24 | 112.76 |
| | (b) Other equity | 14,289.20 | 11,580.60 |
| | **Equity attributable to equity holders of the parent** | **14,404.44** | **11,693.36** |
| | Non-controlling interest | 1,268.29 | 1,394.40 |
| | **Total equity** | **15,672.73** | **13,087.76** |
| (2) | **Non-current liabilities** | | |
| | (a) Financial liabilities | | |
| | (i) Borrowings | 1,939.38 | 2,124.06 |
| | (ii) Lease liabilities | 279.11 | 272.03 |
| | (b) Net employee defined benefit liabilities | 87.00 | 95.66 |
| | (c) Deferred tax liabilities (net) | 313.86 | 331.14 |
| | | **2,619.35** | **2,822.89** |
| (3) | **Current liabilities** | | |
| | (a) Financial liabilities | | |
| | (i) Borrowings | 1,576.84 | 2,002.32 |
| | (ii) Lease liabilities | 102.79 | 102.35 |
| | (iii) Trade payables | | |
| | (a) Total outstanding dues of micro enterprises and small enterprises | 297.92 | 244.91 |
| | (b) Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,196.73 | 1,750.11 |
| | (iv) Other financial liabilities | 299.69 | 369.07 |
| | (b) Net employee defined benefit liabilities | 25.02 | 18.48 |
| | (c) Other liabilities | 1,164.96 | 772.25 |
| | (d) Provisions | 330.85 | 314.10 |
| | | **4,994.80** | **5,573.59** |
| | **Total liabilities (2+3)** | **7,614.15** | **8,396.48** |
| | **Total equity and liabilities (1+2+3)** | **23,286.88** | **21,484.24** |

For and on behalf of the Board of Directors of
Molbio Diagnostics Limited (formerly Molbio Diagnostics Private Limited)

Sangeetha Sriram
Executive Director
DIN: 02103165

Place: Goa
Date: November 05, 2026

S.R. Batliboi & Associates LLP
Bengaluru

MOLBIO DIAGNOSTICS LIMITED
GOA

**Molbio Diagnostics Limited**
(formerly Molbio Diagnostics Private Limited)
CIN: L33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Statement of unaudited consolidated financial results for the quarter and six months ended September 30, 2026**

(Amount in ₹ Million, except as stated otherwise)

| | Particulars | Quarter ended | | | Six months ended | | Year Ended |
|---|---|---|---|---|---|---|---|
| | | September 30, 2026 | June 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | March 31, 2026 |
| | | Unaudited | Unaudited | (Refer note 11) | Unaudited | (Refer note 11) | Audited |
| I | **Income** | | | | | | |
| | Revenue from operations | 2,590.20 | 4,083.76 | 5,802.67 | 6,673.96 | 6,799.75 | 14,456.87 |
| | Other income | 57.74 | 31.00 | 10.92 | 88.74 | 18.52 | 94.83 |
| | **Total income** | **2,647.94** | **4,114.76** | **5,813.59** | **6,762.70** | **6,818.27** | **14,551.70** |
| II | **Expenses** | | | | | | |
| | Cost of raw material and components consumed | 1,129.96 | 1,314.70 | 1,786.42 | 2,444.66 | 2,565.83 | 5,699.23 |
| | Purchase of traded goods | 34.72 | 62.63 | 35.07 | 97.35 | 41.77 | 49.66 |
| | (Increase) / decrease in inventories of finished goods, work-in-progress and traded goods | (170.71) | 119.50 | 403.03 | (51.21) | (31.34) | 12.86 |
| | Employee benefit expenses | 377.97 | 459.20 | 338.82 | 837.17 | 620.60 | 1,452.27 |
| | Depreciation and amortisation expenses | 233.58 | 170.75 | 138.12 | 404.33 | 261.31 | 636.40 |
| | Finance costs | 88.58 | 106.99 | 69.77 | 195.57 | 105.90 | 334.66 |
| | Other expenses | 778.79 | 1,121.89 | 1,557.41 | 1,900.68 | 2,073.54 | 4,028.42 |
| | **Total expenses** | **2,472.89** | **3,355.66** | **4,328.64** | **5,828.55** | **5,637.61** | **12,213.50** |
| III | **Profit / (loss) before tax, share of loss of associates and exceptional items (I - II)** | **175.05** | **759.10** | **1,484.95** | **934.15** | **1,180.66** | **2,338.20** |
| IV | Share of loss of associates, net of tax | - | (0.01) | (7.55) | (0.01) | (16.04) | (21.98) |
| V | **Profit / (loss) before tax and exceptional items (III + IV)** | **175.05** | **759.09** | **1,477.40** | **934.14** | **1,164.62** | **2,316.22** |
| VI | Exceptional items (net) (Refer note 5 and 7) | - | - | - | - | - | 4.85 |
| VII | **Profit / (loss) before tax (V - VI)** | **175.05** | **759.09** | **1,477.40** | **934.14** | **1,164.62** | **2,311.37** |
| VIII | **Tax expenses** | | | | | | |
| | (a) Current tax | 72.21 | 285.46 | 372.43 | 357.67 | 372.43 | 732.93 |
| | (b) Deferred tax (credit) / charge | 25.83 | (53.81) | 36.54 | (27.98) | (36.80) | (62.96) |
| | **Total tax expenses** | **98.04** | **231.65** | **408.97** | **329.69** | **335.63** | **669.97** |
| IX | **Profit/ (loss) for the period / year (VII - VIII)** | **77.01** | **527.44** | **1,068.43** | **604.45** | **828.99** | **1,641.40** |
| X | **Other comprehensive income / (loss)** | | | | | | |
| | (A) Other comprehensive income / (loss) not to be reclassified to profit or loss: | | | | | | |
| | (i) Re-measurement gains / (losses) on defined benefit plan | 6.13 | (3.20) | 0.66 | 2.93 | (2.87) | 1.45 |
| | Income tax effect on above | (1.21) | 0.91 | (0.36) | (0.30) | 0.53 | (0.82) |
| | (B) Other comprehensive income / (loss) to be reclassified to profit or loss: | | | | | | |
| | (i) Exchange gain / (loss) on translating the financial statements of foreign operations | 34.07 | (1.34) | - | 32.73 | - | 153.64 |
| | Income tax effect on above | - | - | - | - | - | - |
| | (ii) Share of other comprehensive gain / (loss) of an associate | - | - | - | - | - | 3.23 |
| | Income tax effect on above | - | - | - | - | - | (0.03) |
| | **Total other comprehensive income/ (loss) for the period / year (net of tax)** | **38.99** | **(3.63)** | **0.30** | **35.36** | **(2.34)** | **157.47** |
| XI | **Total comprehensive income/ (loss) for the period / year (net of tax) (IX + X)** | **116.00** | **523.81** | **1,068.73** | **639.81** | **826.65** | **1,798.87** |
| XII | **Profit / (loss) for the period / year attributable to:** | | | | | | |
| | (a) Owners of the Parent Company | 151.22 | 587.47 | 1,098.00 | 738.69 | 860.86 | 1,665.94 |
| | (b) Non-controlling interest | (74.21) | (60.03) | (29.57) | (134.24) | (31.87) | (24.54) |
| XIII | **Other comprehensive income / (loss) for the period / year attributable to:** | | | | | | |
| | (a) Owners of the Parent Company | 24.80 | (2.92) | 0.57 | 21.88 | (2.07) | 96.51 |
| | (b) Non-controlling interest | 14.19 | (0.71) | (0.27) | 13.48 | (0.27) | 60.96 |
| XIV | **Total comprehensive income / (loss) for the period / year attributable to:** | | | | | | |
| | (a) Owners of the Parent Company | 176.02 | 584.55 | 1,098.57 | 760.57 | 858.79 | 1,762.45 |
| | (b) Non-controlling interest | (60.02) | (60.74) | (29.84) | (120.76) | (32.14) | 36.42 |
| XV | **Paid-up equity share capital (face value ₹ 1 each fully paid)** | 115.24 | 112.76 | 112.76 | 115.24 | 112.76 | 112.76 |
| XVI | **Other equity** | | | | | | 11,580.60 |
| XVII | **Earnings per equity share (EPS) (face value ₹1 each; not annualised for interim periods) (Refer Note 9)** | | | | | | |
| | Basic EPS, computed on the basis of profit / (loss) for the period / year attributable to owners of the Parent Company (₹) | 1.33 | 5.21 | 9.74 | 6.52 | 7.63 | 14.77 |
| | Diluted EPS, computed on the basis of profit / (loss) for the period / year attributable to owners of the Parent Company (₹) | 1.33 | 5.21 | 9.74 | 6.51 | 7.63 | 14.77 |

See accompanying notes to the unaudited consolidated financial results

S.R. Batliboi & Associates LLP Bengaluru

MOLBIO DIAGNOSTICS LIMITED GOA

**Molbio Diagnostics Limited**
(formerly Molbio Diagnostics Private Limited)
CIN: L33125GA2000PLC002909
Registered Office: Plot No. L-46, Phase II D, Verna Industrial Estate, Verna, Goa - 403722
Phone no: +91 832 6724888 ; Website: www.molbiodiagnostics.com; Email: investors@molbiodiagnostics.com

**Unaudited Consolidated Statement of Cash Flows for the six months ended September 30, 2026**

(Amount in ₹ Million, except as stated otherwise)

| Particulars | Six months ended | |
|---|---|---|
| | September 30, 2026 | September 30, 2025 |
| | Unaudited | Unaudited |
| **A. Cash flows from / (used in) operating activities** | | |
| **Profit before tax** | **934.14** | **1,164.62** |
| **Adjustments to reconcile profit before tax to net cash flows:** | | |
| Depreciation and amortisation expenses | 404.33 | 261.31 |
| Impairment allowance on trade receivables and advances | (17.77) | 80.52 |
| Bad debts / advances written off | - | 7.26 |
| Provision for inventories obsolescence | 61.93 | 41.79 |
| Unrealised (gain) / loss on account of foreign exchange fluctuation (net) | (13.53) | 11.91 |
| Liabilities no longer required written back | (2.48) | - |
| (Gain) / loss on sale / discard of property, plant and equipment (net) | (0.21) | 0.40 |
| Loss on termination of lease contracts | 0.85 | - |
| Interest income | (71.75) | (11.20) |
| Finance costs | 187.15 | 98.05 |
| Share based payments to employees | 19.82 | - |
| Share of loss of associates, net of tax | 0.01 | 16.04 |
| **Operating profit before working capital changes** | **1,502.49** | **1,670.70** |
| Working capital adjustments : | | |
| (Increase) / decrease in inventories | (131.21) | (452.41) |
| Decrease / (increase) in trade receivables | 1,078.41 | (3,336.69) |
| (Increase) / decrease in non-current and current other financial and other assets | (165.78) | (257.72) |
| (Decrease) / increase in trade payables, non-current and current other financial, other liabilities and provisions | (124.47) | 374.28 |
| **Cash generated from operations** | **2,159.44** | **(2,001.84)** |
| Direct taxes paid (net of refund) | (488.23) | (390.84) |
| **Net cash flows from / (used in) operating activities (A)** | **1,671.21** | **(2,392.68)** |
| **B. Cash flows (used in) / from investing activities** | | |
| Purchase of property, plant and equipment (including capital work-in- progress, capital advances and payable towards capital goods) and Intangible assets | (335.72) | (225.33) |
| Proceeds from sale of property, plant and equipment | 0.38 | 0.40 |
| Interest income received | 69.14 | 5.53 |
| (Investment) / redemption in bank deposits (net) | (1,143.34) | 65.50 |
| **Net cash flows (used in) / from investing activities (B)** | **(1,409.54)** | **(153.90)** |
| **C. Cash flows from / (used in) financing activities** | | |
| Proceeds from issue of equity shares | 2,000.00 | - |
| Payment of share issue expenses (net) | (73.19) | - |
| Payment of principal portion of lease liabilities | (48.02) | (37.89) |
| Payment of interest portion of lease liabilities | (16.32) | (9.96) |
| Proceeds from long-term borrowings | 103.80 | - |
| Repayment of long-term borrowings | (52.03) | (55.97) |
| (Repayment) / proceeds from short-term borrowings (net) | (849.60) | 773.22 |
| Finance costs paid | (168.35) | (63.15) |
| **Net cash flows from / (used in) financing activities (C)** | **896.29** | **606.25** |
| **Net increase / (decrease) in cash and cash equivalents (A+B+C)** | 1,157.96 | (1,940.33) |
| Cash and cash equivalents at the beginning of the year | 3,357.73 | 632.32 |
| Net foreign exchange difference on cash and cash equivalents | 30.73 | - |
| **Cash and cash equivalents at the end of the period** | **4,546.42** | **(1,308.01)** |
| **Components of cash and cash equivalents** | | |
| Balances with banks | | |
| - On current accounts | 1,345.42 | 93.66 |
| - On deposit accounts | 2,227.51 | - |
| - Deposit with original maturity of less than three months | 1,357.52 | - |
| Cash on hand | 0.83 | 0.78 |
| Overdraft from bank | (384.86) | (1,402.45) |
| **Total cash and cash equivalents** | **4,546.42** | **(1,308.01)** |

For and on behalf of the Board of Directors of
Molbio Diagnostics Limited (formerly Molbio Diagnostics Private Limited)

Sangeetha Sriram
Executive Director
DIN: 02103165

Place: Goa
Date: November 05, 2026

S.R. Batliboi & Associates LLP Bengaluru

MOLBIO DIAGNOSTICS LIMITED GOA

**Notes**

1 The Statement of unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026,of Molbio Diagnostics Limited ( "the Holding Company" or "the Company"), its subsidiaries and associate (together hereinafter referred to as the "Group") have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company in their meeting held on November 05, 2026. The statutory auditors have conducted a limited review of the above unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026.

2 The Statement of unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026 of the Group has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 During the quarter and six months ended September 30, 2026, the Holding Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of ₹ 1 each at an issue price of ₹ 807 per equity share to investors and at an issue price of ₹ 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to ₹ 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to ₹ 7,396.96 Million. The Holding Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026.

Further, out of the total proceeds of ₹ 2,000.00 Million raised through the fresh issue pursuant to IPO, the Holding Company is in the process of utilisation of the proceeds towards the objects of the Offer as disclosed in the offer document and the unutilised proceeds are temporarily invested in fixed deposit and other bank balances.

4 The shareholders of the Holding Company through a special resolution approved the 'Employee Stock Option Plan 2025 ("ESOP 2025"/ "Plan") for creation of ESOP pool of 2,819,000 options having face value of ₹ 1 each. During the quarter and six months ended September 30, 2026, the Holding Company granted 854,480 options to the employees of the Group, of which 5,656 options have been forfeited.

5 On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the "New Labour Codes". The Group had assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by ₹ 35.08 Million and increase in leave liability (compensated absences) by ₹ 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group had presented this incremental amount as exceptional item for the year ended March 31, 2026. The Group continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules thereto.

6 A survey under Section 133A of the Income-tax Act, 1961 ("IT Act"), was carried out at the premises of the Holding Company and Bigtec Private Limited, a subsidiary, by the Income Tax authorities during the year ended March, 2024 followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Holding Company.

The department has raised tax demands aggregating to ₹ 208.71 Million plus interest and penalty, as applicable on the Holding Company, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Holding Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications.

Management believes that the Group has complied with all the applicable provisions of the IT Act with respect to its operations. The Holding Company has paid an amount of ₹ 78.95 Million as at September 30, 2026 under protest in connection with the survey. The management of the Group is confident of favourable outcome and accordingly no adjustments have been made in the unaudited consolidated financial results for the quarter and six months ended September 30, 2026 in this regard.

7 a. During the year ended March 31, 2025, the Holding Company, OptraSCAN, Inc. ("OptraSCAN"), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Holding Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of ₹ 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Holding Company. Further, during the year ended March 31, 2026, the Holding Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of ₹ 2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Holding Company's shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Holding Company. Pursuant to this acquisition, the Group had derecognised its investment in associate as it now holds 60% interest and have gained control as a subsidiary. Accordingly share of loss amounting to ₹ 38.42 million has been recognised as gain on remeasurement of previously held interest in associate and has been disclosed as an exceptional item for the year ended March 31, 2026.

b. As at March 31, 2026, the Holding Company held a stake of 65.47% in Prognosys Medical Systems Private Limited ("PMS"). During the quarter ended June 30, 2026, the Holding Company acquired an additional stake of 4.53% in PMS from the existing shareholders. Consequently, the Holding Company's cumulative shareholding in PMS increased from 65.47% to 70.00%.

8 The operating segment of the Group is identified to be "manufacturing of diagnostic devices, chips, reagents, etc" and the Chief Operating Decision Maker reviews business performance at an overall company level constituting a single segment. Therefore, the disclosure as per Ind AS 108 "Operating segments" and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Group.

9 During the quarter ended September 30, 2025, the Holding Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Companies Act, 2013 in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of ₹ 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended September 30, 2025 and six months ended September 30, 2025 have been adjusted restrospectively and presented accordingly.

10 Unaudited consolidated financial results for the quarter ended September 30, 2026 and six months ended September 30, 2026, includes the unaudited financial results of subsidiaries Bigtec Private Limited, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited, OptraSCAN Inc. w.e.f. November 01, 2025 (associate till October 31, 2025), OptraScan India Private Limited w.e.f. November 01, 2025 (associate till October 31, 2025) and associate Chayagraphics (India) Private Limited.

11 The financial results for the quarter ended September 30, 2025 represent the balancing figures between the unaudited financial results for the six months ended September 30, 2025 and the unaudited financial results for the quarter ended June 30, 2025, both of which were compiled by management. Neither the financial results for the quarter ended September 30, 2025 and six months ended September 30, 2025 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.

**For Molbio Diagnostics Limited**

MOLBIO DIAGNOSTICS LIMITED GOA

**Sangeetha Sriram**
Executive Director
DIN: 02103165

Place : Goa
Date : November 05, 2026

S.R. Batliboi & Associates LLP Bengaluru

Annexure B

**From:** Dr. Kuldeep Singh Sachdeva <drsachdevak@molbiodiagnostics.com>
**Sent:** Thursday, October 22, 2026 12:13:26 pm
**To:** Sriram Natarajan <nsriram@molbiodiagnostics.com>
**Subject:** Tendering Resignation

Dear Mr. Sriram,

I hereby formally tender my resignation from the position of President and Chief Medical Officer, Partnerships and Advocacy at Molbio Diagnostics Limited. My last working day shall be 21st January 2027.

I take this opportunity to acknowledge my tenure with the organization and wish for company continued success in future endeavors.

Regards

Dr Kuldeep Singh Sachdeva
President & Chief Medical Officer
Partnerships & Advocacy
Molbio Diagnostics Ltd
(formerly Molbio Diagnostics Pvt Ltd)

Former NTP Manager/DDG CTD, Government of India
Former HIV AIDS Manager/DDG NACO, Government of India
Former Nodal Officer - India Country Coordination Mechanism (The Global Fund)
Former Nodal Officer - Covid 19 Emergency Response & Health Systems Preparedness
Former Regional Director, South East Asia, The Union



Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

**Annexure- B**

**The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

| Sr. No. | Particulars | Details |
|---|---|---|
| 1 | Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise | Resignation |
| 2 | Date of ~~appointment / re-appointment /~~ cessation (as applicable) ~~& term of appointment/re-appointment~~ | Date of Resignation- October 22, 2026<br><br>Cessation shall be effective from the closure of business hours on January 21, 2027 |
| 3 | Brief profile (in case of appointment) | Not Applicable |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable |

Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
L-46, Phase II D, Verna Industrial Estate
Verna, Goa - 403722, India
+91 832 6724888 www.molbiodiagnostics.com

**Annexure- C**

**The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

| Sr. No. | Particulars | Details |
|---|---|---|
| 1 | Name | M/s Rakesh Hulihalli & Associates, Practising Company Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714) |
| 2 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; | Appointment as Secretarial Auditors of the Company for a first term of five (5) consecutive years commencing from April 01, 2026 to March 31, 2031 pursuant to the provisions of Section 204 of the Companies Act, 2013 and Regulation 24A of the SEBI(Listing Obligations and Disclosure Requirements),Regulation,2015. |
| 3 | Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment; | The Board of Directors at its meeting held on Thursday, November 05,2026 approved the appointment of M/s Rakesh Hulihalli & Associates, Practising Company Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714 as Secretarial Auditors, for a period of five years commencing from FY 2026-27 till 2030-31 subject to approval of the shareholders. |
| 4 | Brief profile (in case of appointment); | **M/s. Rakesh Hulihalli & Associates, Practising Company Secretaries.**<br>The Firm provides professional services in the field of Company Laws, SEBI Regulations, FEMA Regulations including carrying out Secretarial Audits. The Firm is Peer Reviewed by the Institute of Company Secretaries of India. |
| 5 | Disclosure of relationships between directors (in case of appointment of a director). | Not Applicable |